Bibliographies thématiques / Treatment of inflammatory disease / Articles de revues

Articles de revues sur le sujet « Treatment of inflammatory disease »

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Treatment of inflammatory disease.
Auteur : Grafiati
Publié le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Treatment of inflammatory disease ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Fichna, Jakub. « Inflammatory bowel disease treatment ». Pharmacological Reports 68, no 4 (août 2016) : 787–88. http://dx.doi.org/10.1016/j.pharep.2016.05.008.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
2

Leu, Sheng. « A Brief Review Chronic Inflammatory Autoimmune Disease : Multiple Sclerosis Pathogenesis and Treatment ». Neuroscience and Neurological Surgery 1, no 4 (22 novembre 2017) : 01–03. http://dx.doi.org/10.31579/2578-8868/016.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Yadollahpour, Ali. « A Brief Review Chronic Inflammatory Autoimmune Disease : Multiple Sclerosis Pathogenesis and Treatment ». Neuroscience and Neurological Surgery 1, no 4 (22 novembre 2017) : 01–03. http://dx.doi.org/10.31579/2578-8868/023.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

SANTOS, Rachael Miranda dos, Ana Teresa Pugas CARVALHO, Kelly dos Santos SILVA, Selma Petra Chaves SÁ, Aparecida Helena dos SANTOS et Millene Ramos SANDINHA. « INFLAMMATORY BOWEL DISEASE : OUTPATIENT TREATMENT PROFILE ». Arquivos de Gastroenterologia 54, no 2 (16 mars 2017) : 96–100. http://dx.doi.org/10.1590/s0004-2803.201700000-01.

Texte intégral
Résumé :
ABSTRACT BACKGROUND Crohn’s disease and ulcerative colitis are the two major forms of inflammatory bowel disease. The incidence and prevalence of both conditions have increased and are progressively increasing. These diseases are frequently recurrent and clinically highly severe. In Brazil, the lack of epidemiological data related to such diseases has left these patients in a vulnerable state and contributed to increased morbidity. OBJECTIVE To describe the profiles of patients with inflammatory bowel disease treated in an outpatient service in Brazil. METHODS This descriptive, exploratory, and retrospective documentary study with a quantitative approach was performed in an outpatient treatment service for inflammatory bowel disease, at a university polyclinic located in Rio de Janeiro, Brazil, from May to July 2016. The study included 556 patients and was approved by the research ethics committee of the institution (CAAE no. 55179316.6.0000.5259/2016). RESULTS The data showed a high prevalence of inflammatory bowel disease in white female patients. Crohn’s disease was diagnosed in more patients than was ulcerative colitis; the ileocolon was the most commonly affected location in patients with Crohn’s disease. The stenotic phenotype was prevalent in patients with Crohn’s disease. CONCLUSION The prevalence of the stenotic phenotype in Crohn’s disease in relation to others demonstrates the need for further investigations in this field of study in Brazil. In conclusion, the data showed that the epidemiologic profile of the study population is similar to that published in the national and international literature.
Styles APA, Harvard, Vancouver, ISO, etc.
5

Eschenbach, D. « Treatment of Pelvic Inflammatory Disease ». Clinical Infectious Diseases 44, no 7 (1 avril 2007) : 961–63. http://dx.doi.org/10.1086/512200.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
6

Quentin, R., et J. Lansac. « Pelvic inflammatory disease : medical treatment ». European Journal of Obstetrics & ; Gynecology and Reproductive Biology 92, no 2 (octobre 2000) : 189–92. http://dx.doi.org/10.1016/s0301-2115(99)00279-1.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Watanabe, Mamoru, Daisuke Kubota, Masakazu Nagahori et Takanori Kanai. « Treatment of Inflammatory Immunologic Disease 1. Leukocytapheresis for Inflammatory Immunologic Disease (Tentative) ». Internal Medicine 46, no 16 (2007) : 1305–6. http://dx.doi.org/10.2169/internalmedicine.46.1911.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Teml, Alexander, Elke Schaeffeler, Klaus R. Herrlinger, Ulrich Klotz et Matthias Schwab. « Thiopurine Treatment in Inflammatory Bowel Disease ». Clinical Pharmacokinetics 46, no 3 (2007) : 187–208. http://dx.doi.org/10.2165/00003088-200746030-00001.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
9

Gardiner, Sharon J., Evan J. Begg, Ashis Sau, Anthony Marinaki, Richard B. Gearry et Murray L. Barclay. « Thiopurine Treatment in??Inflammatory Bowel??Disease ». Clinical Pharmacokinetics 46, no 9 (2007) : 803–4. http://dx.doi.org/10.2165/00003088-200746090-00007.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
10

Price, Ronald L. « Surgical Treatment of Ocular Inflammatory Disease ». Journal of Pediatric Ophthalmology & ; Strabismus 26, no 2 (mars 1989) : 75. http://dx.doi.org/10.3928/0191-3913-19890301-08.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
11

Balakshina, N. G., et L. I. Kokh. « Surgical treatment of pelvic inflammatory disease ». Bulletin of Siberian Medicine 9, no 1 (28 février 2010) : 70–75. http://dx.doi.org/10.20538/1682-0363-2010-1-70-75.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
12

Lee, Kwang Jae. « Pharmacologic treatment for inflammatory bowel disease ». Journal of the Korean Medical Association 58, no 1 (2015) : 57. http://dx.doi.org/10.5124/jkma.2015.58.1.57.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
13

Park, Jong Beom, et Hyo Jong Kim. « Medical Treatment of Inflammatory Bowel Disease ». Journal of the Korean Medical Association 49, no 12 (2006) : 1164. http://dx.doi.org/10.5124/jkma.2006.49.12.1164.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
14

Dew, M. J. « Medical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 3, no 3 (mai 1987) : 449–59. http://dx.doi.org/10.1097/00001574-198705000-00014.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
15

Peña, A. S. « Medical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 5, no 4 (août 1989) : 487–94. http://dx.doi.org/10.1097/00001574-198908000-00002.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
16

Present, D. H. « Medical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 6, no 4 (août 1990) : 536–42. http://dx.doi.org/10.1097/00001574-199008000-00003.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
17

Campieri, M., P. Gionchetti, A. Belluzzi, C. Brignola, M. Miglioli et L. Barbara. « Medical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 8, no 4 (août 1992) : 663–75. http://dx.doi.org/10.1097/00001574-199208000-00016.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
18

Fazio, Victor W., et Scott A. Strong. « Surgical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 13, no 4 (juillet 1997) : 317–24. http://dx.doi.org/10.1097/00001574-199707000-00007.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
19

Strong, Scott A., et Victor W. Fazio. « Surgical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 15, no 4 (juillet 1999) : 326. http://dx.doi.org/10.1097/00001574-199907000-00009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
20

Strong, Scott A. « Surgical treatment of inflammatory bowel disease ». Current Opinion in Gastroenterology 18, no 4 (juillet 2002) : 441–46. http://dx.doi.org/10.1097/00001574-200207000-00008.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
21

Shanahan, F., et S. Targan. « Medical Treatment of Inflammatory Bowel Disease ». Annual Review of Medicine 43, no 1 (février 1992) : 125–33. http://dx.doi.org/10.1146/annurev.me.43.020192.001013.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
22

Sweet, Richard L. « Treatment of Acute Pelvic Inflammatory Disease ». Infectious Diseases in Obstetrics and Gynecology 2011 (2011) : 1–13. http://dx.doi.org/10.1155/2011/561909.

Texte intégral
Résumé :
Pelvic inflammatory disease (PID), one of the most common infections in nonpregnant women of reproductive age, remains an important public health problem. It is associated with major long-term sequelae, including tubal factor infertility, ectopic pregnancy, and chronic pelvic pain. In addition, treatment of acute PID and its complications incurs substantial health care costs. Prevention of these long-term sequelae is dependent upon development of treatment strategies based on knowledge of the microbiologic etiology of acute PID. It is well accepted that acute PID is a polymicrobic infection. The sexually transmitted organisms,Neisseria gonorrhoeaeandChlamydia trachomatis, are present in many cases, and microorganisms comprising the endogenous vaginal and cervical flora are frequently associated with PID. This includes anaerobic and facultative bacteria, similar to those associated with bacterial vaginosis. Genital tract mycoplasmas, most importantlyMycoplasma genitalium, have recently also been implicated as a cause of acute PID. As a consequence, treatment regimens for acute PID should provide broad spectrum coverage that is effective against these microorganisms.
Styles APA, Harvard, Vancouver, ISO, etc.
23

Pollak, Marcia. « Psychoanalytic Treatment of Inflammatory Gut Disease ». Contemporary Psychology : A Journal of Reviews 41, no 5 (mai 1996) : 480–81. http://dx.doi.org/10.1037/004454.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
24

Prayoonwiwat, Naraporn, et Sasitorn Siritho. « Early treatment of inflammatory demyelinating disease ». Nature Reviews Neurology 9, no 5 (16 avril 2013) : 246–47. http://dx.doi.org/10.1038/nrneurol.2013.59.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
25

Endres, Stefan, Reinhard Lorenz et Klaus Loeschke. « Lipid treatment of inflammatory bowel disease ». Current Opinion in Clinical Nutrition and Metabolic Care 2, no 2 (mars 1999) : 117–20. http://dx.doi.org/10.1097/00075197-199903000-00004.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
26

Herman, Margot L., et Sunanda V. Kane. « Treatment Nonadherence in Inflammatory Bowel Disease ». Inflammatory Bowel Diseases 21, no 12 (décembre 2015) : 2979–84. http://dx.doi.org/10.1097/mib.0000000000000581.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
27

SANDBORN, WILLIAM J., et WILLIAM J. TREMAINE. « Cyclosporine Treatment of Inflammatory Bowel Disease ». Mayo Clinic Proceedings 67, no 10 (octobre 1992) : 981–90. http://dx.doi.org/10.1016/s0025-6196(12)60930-6.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
28

Lindor, Keith D. « Inflammatory Bowel Disease : Diagnosis and Treatment ». Mayo Clinic Proceedings 67, no 10 (octobre 1992) : 1014–15. http://dx.doi.org/10.1016/s0025-6196(12)60941-0.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
29

Kahng, Kim U., et Joel J. Roslyn. « Surgical treatment of inflammatory bowel disease ». Medical Clinics of North America 78, no 6 (novembre 1994) : 1427–41. http://dx.doi.org/10.1016/s0025-7125(16)30109-2.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
30

Pithadia, Anand B., et Sunita Jain. « Treatment of inflammatory bowel disease (IBD) ». Pharmacological Reports 63, no 3 (mai 2011) : 629–42. http://dx.doi.org/10.1016/s1734-1140(11)70575-8.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
31

Magro, Fernando, Gonçalo Cordeiro, Andreia Martins Dias et Maria Manuela Estevinho. « Inflammatory Bowel Disease – Non-biological treatment ». Pharmacological Research 160 (octobre 2020) : 105075. http://dx.doi.org/10.1016/j.phrs.2020.105075.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
32

Schwartz, David A., et Brad E. Maltz. « Treatment of Fistulizing Inflammatory Bowel Disease ». Medical Clinics of North America 94, no 1 (janvier 2010) : 19–34. http://dx.doi.org/10.1016/j.mcna.2009.08.020.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
33

Leone, Charles R., et William C. Lloyd. « Treatment Protocol for Orbital Inflammatory Disease ». Ophthalmology 92, no 10 (octobre 1985) : 1325–31. http://dx.doi.org/10.1016/s0161-6420(85)33854-x.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
34

MacDermott, Richard P., et Andrew Conn. « Inflammatory bowel disease : Diagnosis and treatment ». Gastroenterology 102, no 2 (février 1992) : 738. http://dx.doi.org/10.1016/0016-5085(92)90137-n.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
35

Sachar, David B. « Cyclosporine Treatment for Inflammatory Bowel Disease ». New England Journal of Medicine 321, no 13 (28 septembre 1989) : 894–96. http://dx.doi.org/10.1056/nejm198909283211309.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
36

Schwartz, David A., et Brad E. Maltz. « Treatment of Fistulizing Inflammatory Bowel Disease ». Gastroenterology Clinics of North America 38, no 4 (décembre 2009) : 595–610. http://dx.doi.org/10.1016/j.gtc.2009.07.009.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
37

&NA;. « Treatment Protocol for Orbital Inflammatory Disease ». Ophthalmic Plastic & ; Reconstructive Surgery 2, no 1 (1986) : 55. http://dx.doi.org/10.1097/00002341-198601040-00044.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
38

Sweet, Richard L. « Treatment strategies for pelvic inflammatory disease ». Expert Opinion on Pharmacotherapy 10, no 5 (avril 2009) : 823–37. http://dx.doi.org/10.1517/14656560902823816.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
39

Hodgson, H. J. F. « Inflammatory bowel disease - diagnosis and treatment ». Gut 33, no 3 (1 mars 1992) : 425. http://dx.doi.org/10.1136/gut.33.3.425-a.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
40

Raizman, Michael. « Surgical Treatment of Ocular Inflammatory Disease ». Archives of Ophthalmology 107, no 5 (1 mai 1989) : 650. http://dx.doi.org/10.1001/archopht.1989.01070010668020.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
41

Grimes, David A. « Antibiotic Treatment of Pelvic Inflammatory Disease ». JAMA 256, no 23 (19 décembre 1986) : 3223. http://dx.doi.org/10.1001/jama.1986.03380230047023.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
42

Sellin, Joseph. « Treatment targets in inflammatory bowel disease ». Advanced Drug Delivery Reviews 57, no 2 (janvier 2005) : 217–18. http://dx.doi.org/10.1016/j.addr.2004.08.010.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
43

Matsumoto, Takayuki. « Treatment of Inflammatory Immunologic Disease 2. Anti-Cytokine Therapies in Inflammatory Bowel Disease ». Internal Medicine 46, no 16 (2007) : 1307–9. http://dx.doi.org/10.2169/internalmedicine.46.1912.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
44

Melestean-Bratu, Madalina-Ioana, Antoine Edu, Mihaela Bujor, Stelian Conci, Florin Isopescu, Radu Mateescu, Mihai Dumitrascu, Florica Sandru, Andreea Carp-Veliscu et Claudia Mehedintu. « Pelvic inflammatory disease ». Romanian Journal of Medical Practice 16, S6 (15 décembre 2021) : 5–7. http://dx.doi.org/10.37897/rjmp.2021.s6.1.

Texte intégral
Résumé :
Pelvic inflammatory disease (PID) is a very common condition among women of reproductive age. It is also a common reason for presenting to the emergency room. Although it often presents with mild symptoms, it is very important to consider it in any sexually active patient in order to start treatment as soon as possible and avoid complications.
Styles APA, Harvard, Vancouver, ISO, etc.
45

Wei, Yanting We, Hongning Su, Dandan Geng, Weimin Huo, Miao Zhou, Jiajia Li et Ke He. « Clinical effect of Hongteng decoction combined with levofloxacin in the treatment of chronic pelvic inflammatory disease and its effect on inflammatory factors ». ISP Medicine 3, no 1 (1 janvier 2021) : 1–8. http://dx.doi.org/10.52274/ispmed20210307.

Texte intégral
Résumé :
Objective: To explore the clinical therapeutic effect of Hongteng decoction combined with levofloxacin on chronic pelvic inflammatory disease (CPID) patients and its effect on the expression of inflammatory factors. Methods: 72 patients with CPID who were diagnosed and treated in the Fourth Hospital of Shijiazhuang City from January 2020 to December 2020 were selected and randomly divided into observation group (n = 36) and control group (n = 36). The control group was treated with levofloxacin and the observation group was treated with Hongteng decoction retention enema on the basis of the control group. Both groups were treated continuously for 2 courses. The clinical therapeutic effects of the two groups were compared, and the changes of related inflammatory indexes such as interleukin-2 (IL-2), interleukin-10 (IL-10), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were compared between the two groups before and after treatment. The score of quality of life and the occurrence of adverse reactions before treatment were compared. Results: The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). The inflammatory indexes of IL-2, IL-10, CRP and TNF-α in 2 groups before treatment were compared, and there was no statistical significance (P>0.05). After treatment, the expression of IL-2 and IL-10 in the observation group was higher than that in the control group, and the expression of CRP and TNF-α was lower than that in the control group, with statistical significance (P<0.05). There were no significant differences in physical pain, life function, social function and mental health scores between the two groups before treatment (P>0.05). After treatment, scores of physical pain, life function, social function and mental health in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05). After treatment, there was no significant difference in the incidence of adverse reactions between the observation group and the control group (P>0.05). Conclusion: Hongteng decoction combined with levofloxacin has definite efficacy in the treatment of CPID, which can effectively improve the clinical symptoms of patients and inhibit inflammatory response, and is worthy of clinical promotion.
Styles APA, Harvard, Vancouver, ISO, etc.
46

Hodson, Alexander. « Pelvic Inflammatory Disease ». InnovAiT : Education and inspiration for general practice 2, no 9 (26 août 2009) : 517–21. http://dx.doi.org/10.1093/innovait/inp082.

Texte intégral
Résumé :
Pelvic inflammatory disease (PID), infection and inflammation of the upper female genital tract, is a common condition managed by General Practitioners (GPs). It accounts for one in 60 consultations in women of reproductive age. Early diagnosis, management and, if necessary, referral is essential to help prevent serious long-term complications such as ectopic pregnancy, infertility and chronic pelvic pain. This article outlines the causes, clinical features, treatment and follow-up of PID.
Styles APA, Harvard, Vancouver, ISO, etc.
47

HUSNÍK, R., J. KLIMEŠ, K. TOMANOVÁ, J. SMOLA, R. HALOUZKA, F. TICHÝ et J. BRÁZDIL. « Lawsonia intracellularis in a dog with inflammatory bowel disease ». Veterinární Medicína 48, No. 5 (30 mars 2012) : 141–45. http://dx.doi.org/10.17221/5761-vetmed.

Texte intégral
Résumé :
A two-year-old male German short-haired pointer was presented with a 1.5-year history of intermittent small-bowel diarrhoea. Inflammatory bowel disease (chronic lymphocytic-plasmacytic gastritis, enteritis and colitis) was diagnosed on the basis of histological examination of biopsies obtained on repeated endoscopy and by exclusion of other possible causes. Warthin-Starry silver staining of stomach mucosa revealed the presence of gastric spiral organisms. The evidence of L. intracellularis was provided by a positive nested polymerase chain reaction in one biopsy of duodenal mucosa and in one rectal smear. In 5 blood sera collected over a period of 8 months the IgG antibodies to L. intracellularis were found by an indirect fluorescent antibody test. Treatment with oral prednisone led only to a temporary improvement.
Styles APA, Harvard, Vancouver, ISO, etc.
48

Rakha, Serena S. « Pelvic inflammatory disease ». InnovAiT : Education and inspiration for general practice 11, no 4 (2 mars 2018) : 198–200. http://dx.doi.org/10.1177/1755738017750998.

Texte intégral
Résumé :
Pelvic inflammatory disease (PID) is a generalised term that describes infection of the upper genital tract in women. It is commonly caused by the sexually transmitted infections Chlamydia Trachomatis and Neisseria Gonorrhoea. Clinical features of PID include pelvic pain, deep dyspareunia, cervical motion tenderness and adnexal tenderness. Complications include infertility, ectopic pregnancy and chronic pelvic pain. Therefore, it is important for GPs to have a high index of suspicion when women present with symptoms of PID and to initiate antibiotic treatment before vaginal swab results are known.
Styles APA, Harvard, Vancouver, ISO, etc.
49

Gargallo-Puyuelo, Carla, Erika Alfambra, Jose García-Erce et Fernando Gomollon. « Iron Treatment May Be Difficult in Inflammatory Diseases : Inflammatory Bowel Disease as a Paradigm ». Nutrients 10, no 12 (11 décembre 2018) : 1959. http://dx.doi.org/10.3390/nu10121959.

Texte intégral
Résumé :
Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
Styles APA, Harvard, Vancouver, ISO, etc.
50

Brenner, Erica J., et Millie D. Long. « Diagnosis and treatment of dermatologic diseases in inflammatory bowel disease ». Current Opinion in Gastroenterology 35, no 4 (juillet 2019) : 330–36. http://dx.doi.org/10.1097/mog.0000000000000538.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
Vous pouvez également être intéressé par les bibliographies sur le sujet « Treatment of inflammatory disease » pour d’autres types de sources :
Thèses Livres
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie